3 Matching Annotations
  1. Aug 2022
  2. www.biorxiv.org www.biorxiv.org
    Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages
    1
    1. jackiekrauss 29 Aug 2022

      Iketani, S., Liu, L., Guo, Y., Liu, L., Huang, Y., Wang, M., Luo, Y., Yu, J., Yin, M. T., Sobieszczyk, M. E., Huang, Y., Wang, H. H., Sheng, Z., & Ho, D. D. (2022). Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages (p. 2022.02.07.479306). bioRxiv. https://doi.org/10.1101/2022.02.07.479306

      is:preprint lang:en COVID-19 Omicron mutation spike glycoprotein antibody evasion prevalence unique spike mutation antigenic characterization sublineage mRNA vaccine antigenically equidistant efficacy resistance monoclonal antibody therapy
    Visit annotations in context

    Tags

    Annotators

    URL

    biorxiv.org/content/10.1101/2022.02.07.479306v1
  3. Mar 2022
  4. www.forbes.com www.forbes.com
    Birth Of The Omicron Family: BA.1, BA.2, BA.3. Each As Different As Alpha Is From Delta.
    1
    1. NatasjaDerbyMcCabe 30 Mar 2022

      Haseltine, W. A. (n.d.). Birth Of The Omicron Family: BA.1, BA.2, BA.3. Each As Different As Alpha Is From Delta. Forbes. Retrieved 30 March 2022, from https://www.forbes.com/sites/williamhaseltine/2022/01/26/birth-of-the-omicron-family-ba1-ba2-ba3-each-as-different-as-alpha-is-from-delta/

      is:blogpost lang:en COVID-19 Omicron ba.1 ba.2 ba.3 United States Nepal Denmark Phillipines India prolific sublineage East Africa Wuhan Spike protein transmissibility higher transmission membrane-to-membrane fusion endosomal
    Visit annotations in context

    Tags

    Annotators

    URL

    forbes.com/sites/williamhaseltine/2022/01/26/birth-of-the-omicron-family-ba1-ba2-ba3-each-as-different-as-alpha-is-from-delta/
  5. Feb 2022
  6. www.bmj.com www.bmj.com
    Covid-19: What do we know about omicron sublineages?
    1
    1. lucyparfitt16 13 Feb 2022

      Mahase, E. (2022). Covid-19: What do we know about omicron sublineages? BMJ, 376, o358. https://doi.org/10.1136/bmj.o358

      is:article lang:en COVID-19 Omicron sublineage transmissibility delta severity research hospitalization risk reinfection vaccine protection mortality booster treatment antibody-based treatment growth rate data effectiveness vaccine efficacy dose subvariant
    Visit annotations in context

    Tags

    Annotators

    URL

    bmj.com/content/376/bmj.o358